EZH2 and hematologic disorder: Furthermore, Yang et al. recently proposed targeting USP47 with a small molecule inhibitor as a novel potential therapy for diffuse large B-cell lymphoma and other hematologic malignancies characterized by mutant EZH2 expression11.